Market
Keros Therapeutics resume high-dose TROPOS trial arms by Q2 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Keros Therapeutics official press releases or regulatory filings
Story
Keros Therapeutics Halts Dosing in Phase 2 PAH Trial Due to Safety Concerns
Dec 12, 2024, 12:02 PM
Keros Therapeutics Inc. (Nasdaq: KROS) has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its ongoing Phase 2 TROPOS trial due to safety concerns related to pericardial effusion adverse events. The trial, which evaluates cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH), remains fully enrolled. Dosing in the 1.5 mg/kg treatment arm continues following a risk and benefit assessment by the independent Data Monitoring Committee (DMC). The company has informed investigators and regulatory authorities, including the FDA, of this decision and plans to present topline data from all treatment arms in the second quarter of 2025. Shares of Keros Therapeutics plunged following the announcement.
View original story
Similar markets
No • 50%
Yes • 50%
Positive efficacy and safety results • 25%
Negative efficacy and safety concerns • 25%
Negative efficacy, but good safety • 25%
Positive efficacy, but safety concerns • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Successful • 25%
Not Announced • 25%
Partially Successful • 25%
Unsuccessful • 25%
No • 50%
Yes • 50%